By Fineline Cube Bio-heart Biological Technology Co., Ltd. (HKG: 2185) announced that China’s National Medical Products Administration (NMPA) has granted marketing approval for the company’s independently developed Bio-heart Biodegradable Drug-Eluting Stent (BRS) system, indicated for the treatment of patients with ischemic heart disease caused by native coronary artery lesions to improve coronary artery lumen diameter.
Regulatory Milestone
| Item | Detail |
|---|---|
| Agency | NMPA (China) |
| Approval Type | Full marketing approval |
| Product | Bioheart Biodegradable Drug-Eluting Stent (BRS) |
| Indication | Treatment of ischemic heart disease caused by native coronary artery lesions |
| Primary Objective | Improve coronary artery lumen diameter |
| Procedure | Percutaneous coronary intervention (PCI) |
Product Profile & Mechanism of Action
- Technology: Fully biodegradable stent system designed for complete absorption by the human body over time
- Function: Temporarily maintains vessel patency during critical healing phase
- Clinical Benefits:
- Effectively reduces elastic recoil and acute vessel occlusion
- Prevents restenosis through controlled drug elution
- Restores natural vessel function post-absorption
- Innovation: Represents a next-generation solution in coronary artery disease management, eliminating permanent metallic implants
Market Impact & Strategic Position
- Market Opportunity: Addresses China’s significant burden of coronary artery disease, a leading cause of mortality nationwide
- Competitive Advantage: As a domestically developed BRS system, aligns with China’s strategic emphasis on indigenous medical innovation
- Technology Leadership: Positions Bio-heart Biological Technology Co., Ltd. at the forefront of China’s cardiovascular medical device sector
- Long-term Value: Offers improved patient outcomes through temporary support followed by complete absorption, potentially reducing long-term complications associated with permanent stents
Forward-Looking Statements
This brief contains forward-looking statements regarding market positioning and strategic advantages. Actual commercial performance may vary based on market adoption, competitive dynamics, and healthcare policy developments.-Fineline Info & Tech